source,rank,nct_number,title,acronym,status,study_results,conditions,interventions,outcome_measures,sponsor_collaborators,gender,age,phases,enrollment,funded_bys,study_type,study_designs,other_i_ds,start_date,primary_completion_date,completion_date,first_posted,results_first_posted,last_update_posted,locations,study_documents,url,drug
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,1,NCT04390594,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,SEN-CoV-Fadj,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + Azithromycin,SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation,"Institut Pasteur de Dakar|Fann Hospital, Senegal|Ministry of Health, Senegal|Diamniadio Children Hospital, Senegal|Dalal Jamm Hospital, Senegal",All,"15 Years and older   (Child, Adult, Older Adult)",Phase 3,258,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-002,"June 1, 2020","December 1, 2020","June 1, 2021","May 15, 2020",NA,"May 27, 2020","Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal|Diamniadio Children Hospital, Diamniadio, Senegal|Dalal Jamm Hospital, Guédiawaye, Senegal",NA,https://ClinicalTrials.gov/show/NCT04390594,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,2,NCT04321278,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NA,Recruiting,No Results Available,"Coronavirus Infections|Pneumonia, Viral",Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,"Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype",Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30155020.5.1001.0071,"March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",NA,"May 27, 2020","Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil|Hospital e Clínica São Roque, Ipiaú, BA, Brazil|Hospital da Cidade, Salvador, BA, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, CE, Brazil|Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil|Hospital Brasilia, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil|Hospital Evangélico de Vila Velha, Vila Velha, ES, Brazil|Secretaria de Estado de Saúde de Goias, Goiânia, GO, Brazil|Santa Casa de Misericórdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil|Hospital Santa Paula, Passos, MG, Brazil|Santa Casa da Misericordia - UTI (São João Del Rey), São João Del Rei, MG, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Adventista de Belém, Belém, Pará, Brazil|Hospital Adventista de Belem, Belem, PA, Brazil|Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil|Liga Paranaense de Combate ao Câncer, Curitiba, PR, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil|Hospital São Lucas, Rio De Janeiro, RJ, Brazil|Hospital Maternidade PROMATER, Natal, RN, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, RS, Brazil|Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Hospital Nereu Ramos, Florianópolis, SC, Brazil|Hospital Universitário Polydoro Ernani de São Thiago/HU - UFSC, Florianópolis, SC, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital Dona Helena, Joinville, SC, Brazil|Hospital Municipal Sao Jose, Joinville, SC, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil|Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil|nstituto de Pesquisa Clínica de Campinas, Campinas, SP, Brazil|Fundação do ABC (Hospital Estadual Mário Covas), Santo André, SP, Brazil|AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil|Casa de Saude Santa Marcelina, São Paulo, SP, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil|Hospital Moriah, São Paulo, SP, Brazil|Hospital Nove de Julho, São Paulo, SP, Brazil|Hospital Santa Paula, São Paulo, SP, Brazil|Hospital São Camilo Pompeia, São Paulo, SP, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital Vila Santa Catarina, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",NA,https://ClinicalTrials.gov/show/NCT04321278,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,3,NCT04374903,Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients,COVID19-HOPE,Not yet recruiting,No Results Available,COVID-19 Patients,Drug: HCQ & AZ vs HCQ+SIR,Time to Clinical improvement (TTCI)|Clinical failure defined as death or need for Intubation and mechanical ventilation|Adverse effects|QT interval prolongation|Failure to continue assigned therapy|Time to viral clearance,King Hussein Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20 KHCC 74,"May 1, 2020","August 1, 2020","September 1, 2020","May 5, 2020",NA,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",NA,https://ClinicalTrials.gov/show/NCT04374903,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,4,NCT04345861,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),COVIDOC,Recruiting,No Results Available,"Coronavirus Infection|Pneumonia, Viral",Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin,Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).|Clinical status assessed by ordinal scale|transfer to ICU|Length of hospital day|Hospital Mortality|Need to Mechanical Ventilation|Occurence of grade 3-4 adverse event|QTc Lengthening|Evolution of pulmonary CT scan images,"University Hospital, Montpellier",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RECHMPL20_168,"April 11, 2020","September 6, 2020","April 6, 2021","April 15, 2020",NA,"April 24, 2020","Montpellier University hospital, Montpellier, France",NA,https://ClinicalTrials.gov/show/NCT04345861,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,5,NCT04322123,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),Coalition-I,"Active, not recruiting",No Results Available,Coronavirus Infections,Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days,Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brazil COVID Coalition I Trial,"April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",NA,"June 1, 2020","Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil",NA,https://ClinicalTrials.gov/show/NCT04322123,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,6,NCT04349592,Qatar Prospective RCT Of Therapy Eliminating Covid Transmission,Q-PROTECT,Not yet recruiting,No Results Available,Covid19,Drug: Hydroxychloroquine + Azithromycin|Drug: Hydroxychloroquine + Placebo|Other: Placebo + Placebo,Proportion of virologically cured (no virus detected) cases at day 6|The dichotomous virologic shedding endpoint as assessed at two weeks after study entry|Quantitative viral load (assessed with each virology testing set),Hamad Medical Corporation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,456,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MRC-05-001,"April 14, 2020","May 14, 2020","May 30, 2020","April 16, 2020",NA,"April 16, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04349592,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,7,NCT04355052,"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus",COSTA,Recruiting,No Results Available,COVID - 19,Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin,clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death,Sheba Medical Center,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,250,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7092-20-SMC,"April 11, 2020","October 11, 2020","December 11, 2020","April 21, 2020",NA,"April 21, 2020","Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel",NA,https://ClinicalTrials.gov/show/NCT04355052,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,8,NCT04358081,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NA,Recruiting,No Results Available,Pneumonia,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CJWT629A12301,"May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",NA,"May 21, 2020","Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Columbia, Missouri, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States",NA,https://ClinicalTrials.gov/show/NCT04358081,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,9,NCT04347031,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,NA,"Active, not recruiting",No Results Available,"Pneumonia, Viral|Respiratory Failure",Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab,1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2,Burnasyan Federal Medical Biophysical Center,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FL-01/20,"April 8, 2020","August 1, 2020","August 1, 2020","April 15, 2020",NA,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",NA,https://ClinicalTrials.gov/show/NCT04347031,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,10,NCT04338698,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",PROTECT,Not yet recruiting,No Results Available,COVID 19,Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin,Laboratory Result|Clinical Outcome,Shehnoor Azhar|Federal Task Force on Science & Technology notified by Government of Pakistan|University of Health Sciences Lahore,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12(06)/2016-Coord,"April 7, 2020","September 1, 2020","November 30, 2020","April 8, 2020",NA,"April 10, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04338698,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,11,NCT04365231,Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,HASCOPT,Not yet recruiting,No Results Available,COVID19,Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients,Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit,"Hospital St. Joseph, Marseille, France",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HASCOPT2020,April 2020,June 2020,January 2021,"April 28, 2020",NA,"April 28, 2020","Hopital Saint Joseph, Marseille, Paca, France",NA,https://ClinicalTrials.gov/show/NCT04365231,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,12,NCT04329832,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,HAHPS,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score,"Intermountain Health Care, Inc.|University of Utah",All,"18 Years and older   (Adult, Older Adult)",Phase 2,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1051355,"March 30, 2020","December 31, 2020","December 31, 2021","April 1, 2020",NA,"June 2, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",NA,https://ClinicalTrials.gov/show/NCT04329832,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,13,NCT04371406,Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients,MG-COVID,Not yet recruiting,No Results Available,Covid-19,Drug: Hydroxychloroquine and Azithromycin|Dietary Supplement: Azinc,Rate of patients with occurrence of an unfavorable outcome between randomization and day 14|Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|The all-cause mortality rate at day 14|The all-cause mortality rate at day 28|Rate of patients with occurrence of an unfavorable outcome between randomization and day 28|The rate of use of mechanical ventilation at day 14|The rate of use of mechanical ventilation at day 28|The Intensive Care Unit admission rate at day 14|The Intensive Care Unit admission rate at day 28|Number of days of hospitalization for any cause between day 0 and day 14|Number of days of hospitalization for any cause between day 0 and day 28|The time to resolution of all COVID symptoms at day 14|The time to resolution of all COVID symptoms atday 28|The rate of use of oxygen therapy at day 14|The rate of use of oxygen therapy at day 28|The rate of use of secondary antibiotic therapy (after day 2) at day 14|The rate of use of secondary antibiotic therapy (after day 2) at day 28|Clinical status at day 14|Clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|The rate of patients with treatment withdrawal|Ancillary virological study : rate of patients with negative viral load at day 8|Ancillary virological study : rate of patients with negative viral load at day 14,Assistance Publique - Hôpitaux de Paris,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,2770,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200447|2020-001702-35,"May 2, 2020","August 2, 2020","September 2, 2020","May 1, 2020",NA,"May 1, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04371406,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,14,NCT04334382,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,HyAzOUT,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days,"Intermountain Health Care, Inc.|University of Utah|Utah Department of Health",All,"45 Years and older   (Adult, Older Adult)",Phase 3,1550,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1051360,"April 2, 2020","December 31, 2020","December 31, 2021","April 6, 2020",NA,"April 9, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",NA,https://ClinicalTrials.gov/show/NCT04334382,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,15,NCT04341870,"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",CORIMUNO-VIRO,Suspended,No Results Available,COVID19|SARS-CoV-2 Infection,Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine,"Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-3,"April 11, 2020","May 8, 2020",August 2020,"April 10, 2020",NA,"May 6, 2020","AP-HP Hôpital Avicenne, Bobigny, France|AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France|AP-HP Hôpital Beaujon, Clichy, France|AP-HP Hôpital Pitié Salpétrière, Paris, France|AP-HP Hôpital Saint Antoine, Paris, France",NA,https://ClinicalTrials.gov/show/NCT04341870,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,16,NCT04348474,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,NA,Suspended,No Results Available,Covid-19,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets,Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity,Azidus Brasil,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,200,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIAPRE0420OR,"April 20, 2020","June 30, 2020","July 31, 2020","April 16, 2020",NA,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",NA,https://ClinicalTrials.gov/show/NCT04348474,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,17,NCT04336332,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NA,Recruiting,No Results Available,SARS-CoV-2|COVID-19,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood,"Rutgers, The State University of New Jersey",All,"18 Years and older   (Adult, Older Adult)",Phase 2,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002011|Pro2020000712,"April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",NA,"May 8, 2020","Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States",NA,https://ClinicalTrials.gov/show/NCT04336332,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,18,NCT04405921,"Hydroxychloroquine, Azithromycin in the Treatment of Covid-19",PACTT,Not yet recruiting,No Results Available,SARS-CoV-2 Pneumonia|COVID-19,Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 250 MG,"Clinical recovery at day-14, from the start of treatment.|Viral Clearance via RT-PCR at day 5- 7-10 and day 14",Centre Hôpital Universitaire Farhat Hached,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",PACTT,July 2020,December 2020,March 2021,"May 28, 2020",NA,"June 4, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04405921,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,19,NCT04346693,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,NA,"Active, not recruiting",No Results Available,Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia,Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation,The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study,Burnasyan Federal Medical Biophysical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAL-05-04-2020,"April 8, 2020",December 2020,December 2020,"April 15, 2020",NA,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",NA,https://ClinicalTrials.gov/show/NCT04346693,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,20,NCT04329572,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,NA,Suspended,No Results Available,COVID-19,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets,"Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days",Azidus Brasil,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,400,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIAPRE0320OR,"April 23, 2020","May 31, 2020","June 30, 2020","April 1, 2020",NA,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",NA,https://ClinicalTrials.gov/show/NCT04329572,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,21,NCT04359953,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",COVID-Aging,Not yet recruiting,No Results Available,COVID-19 Infection,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan,"Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI (Hung et al 2017)|Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living (ADL) Activity of Daily Living)|Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)|The number and dose of added corticosteroids, immonumodulators or immunosuppressants","University Hospital, Strasbourg, France",All,"60 Years and older   (Adult, Older Adult)",Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7747,"April 24, 2020","June 1, 2021","June 1, 2021","April 24, 2020",NA,"April 24, 2020","CHU de Strasbourg, Strasbourg, France",NA,https://ClinicalTrials.gov/show/NCT04359953,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,22,NCT04358068,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NA,Recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,"Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset",National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2000,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ACTG A5395|38720,"May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",NA,"June 9, 2020","Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|University of Southern California CRS, Los Angeles, California, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Weill Cornell Uptown CRS, New York, New York, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Case Clinical Research Site, Cleveland, Ohio, United States|Ohio State University CRS, Columbus, Ohio, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",NA,https://ClinicalTrials.gov/show/NCT04358068,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,23,NCT04341207,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,ONCOVID,Recruiting,No Results Available,Cancer & COVID 19,Drug: Hydroxychloroquine|Drug: Azithromycin,Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin,"Gustave Roussy, Cancer Campus, Grand Paris",All,"18 Years and older   (Adult, Older Adult)",Phase 2,1000,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-001250-21|2020/3078,"April 3, 2020",April 2022,April 2022,"April 10, 2020",NA,"April 10, 2020","Gustave Roussy, Villejuif, Val De Marne, France",NA,https://ClinicalTrials.gov/show/NCT04341207,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,24,NCT04347512,EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA,TEACHCOVID,Withdrawn,No Results Available,"Sars-CoV-2, Community-Acquired Pneumonia,COVID-19",Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm,"Rate of patients reaching a significant hypoxemia, in each arms.","University Hospital, Strasbourg, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7783,"June 2, 2020","June 2, 2020","June 2, 2020","April 15, 2020",NA,"June 4, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04347512,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,25,NCT04392128,Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE),HYACINTHE,Not yet recruiting,No Results Available,COVID19|Hematologic Malignancy,Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule,Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.|Clinical evolution|Proportion of patients progressing to a severe form|Mortality|Evaluation of viral load drop|Tolerance of study treatment|Evaluation of the seroconversion|NK immunological study|Hospitalisation duration|Impact of the study treatment on the treatment of the hematological disease|Monitoring of the QT space|Dosage of residual concentration of azithromycine and hydroxychloroquine.|T immunological study,Institut de Cancerologie Strasbourg Europe,All,"18 Years and older   (Adult, Older Adult)",Phase 2,114,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-005|2020-002002-45,"May 12, 2020","December 31, 2020","January 31, 2021","May 18, 2020",NA,"May 20, 2020","Institut de Cancérologie Strasbourg Europe, Strasbourg, France",NA,https://ClinicalTrials.gov/show/NCT04392128,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,26,NCT04370782,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,NA,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline,Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms,"St. Francis Hospital, New York",All,"30 Years and older   (Adult, Older Adult)",Phase 4,750,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-21,"April 28, 2020","September 30, 2020","December 31, 2020","May 1, 2020",NA,"May 18, 2020","St Francis Hospital, Roslyn, New York, United States",NA,https://ClinicalTrials.gov/show/NCT04370782,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,27,NCT04332094,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",TOCOVID,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin,In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III,All,"18 Years and older   (Adult, Older Adult)",Phase 2,276,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIBSP-COV-2020-23,"April 2, 2020",September 2020,October 2020,"April 2, 2020",NA,"April 7, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",NA,https://ClinicalTrials.gov/show/NCT04332094,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,28,NCT04335552,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",NA,Recruiting,No Results Available,SARS-CoV-2,Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin,World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events,Duke University,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00105339,"April 17, 2020","August 1, 2020","August 1, 2020","April 6, 2020",NA,"April 24, 2020","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States",NA,https://ClinicalTrials.gov/show/NCT04335552,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,29,NCT04359316,Azithromycin in Hospitalized COVID-19 Patients,AIC,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events,Shahid Beheshti University of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Azithromycin in COVID-19,"April 20, 2020","May 3, 2020","May 5, 2020","April 24, 2020",NA,"April 24, 2020","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",NA,https://ClinicalTrials.gov/show/NCT04359316,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,30,NCT04328272,Effectiveness of Hydroxychloroquine in Covid-19 Patients,Covid,Not yet recruiting,No Results Available,COVID19,Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets,National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers,"Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad",All,18 Years to 50 Years   (Adult),Phase 3,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Ath/ct101/22/3,"March 28, 2020","May 28, 2020","June 28, 2020","March 31, 2020",NA,"April 2, 2020","Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan",NA,https://ClinicalTrials.gov/show/NCT04328272,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,31,NCT04374552,Asymptomatic COVID-19 Trial,ACT,Not yet recruiting,No Results Available,SARS-CoV-2 Infection,Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo,The primary outcome is the rate of decline in viral load over the 10 days after randomization,"Rutgers, The State University of New Jersey",All,"20 Years and older   (Adult, Older Adult)",Phase 2,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro2020000872,"May 5, 2020",November 2020,April 2021,"May 5, 2020",NA,"May 5, 2020","Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States",NA,https://ClinicalTrials.gov/show/NCT04374552,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,32,NCT04354597,Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients,MOPHYDA,Not yet recruiting,No Results Available,COVID-19,Drug: HCQ & AZ,Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate,King Hussein Cancer Center,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20 KHCC 67,"May 1, 2020","August 15, 2020","October 15, 2020","April 21, 2020",NA,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",NA,https://ClinicalTrials.gov/show/NCT04354597,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,33,NCT04344379,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,PREP-COVID,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",APHP200386|2020-001273-73,"April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",NA,"April 24, 2020","Hopial Avicenne, Bobigny, France|Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France|Hôpital Saint Antoine, Paris, France|Hôpital Broca, Paris, France|Hôpital La Pitié-Salpétrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital européen Georges Pompidou, Paris, France|Hôpital Necker, Paris, France",NA,https://ClinicalTrials.gov/show/NCT04344379,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,34,NCT04361461,Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),NA,Not yet recruiting,No Results Available,Coronavirus Infections|SARS-CoV 2|SARS (Severe Acute Respiratory Syndrome)|Pulmonary Disease,Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin,Individual response rate|All-cause mortality|Duration of mechanical ventilation|Proportion of patients which needed mechanical ventilation during study|World Health Organization (WHO) Ordinal scale|Duration of hospitalization|Rates of drug discontinuation,Apsen Farmaceutica S.A.|Hospital São Paulo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APS001/2020,"May 4, 2020","November 4, 2020","November 4, 2020","April 24, 2020",NA,"April 24, 2020","Apsen Farmacêutica S.A., São Paulo, Brazil",NA,https://ClinicalTrials.gov/show/NCT04361461,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,35,NCT04395768,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,NA,Not yet recruiting,No Results Available,COVID19,Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12,Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support,"National Institute of Integrative Medicine, Australia|Catholic Health Initiatives",All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Alliance-COVID19,"May 25, 2020","May 31, 2021","December 31, 2021","May 20, 2020",NA,"May 20, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04395768,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,36,NCT04363203,VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),VA-REACH,"Active, not recruiting",No Results Available,SARS-CoV-2|COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet,"Days to resolution of cough, fever and shortness of breath|Days to resolution of all COVID-19 symptoms|All cause hospitalization|All cause mortality|COVID-19 specific mortality|COVID-19 specific hospitalization",Salomeh Keyhani MD|San Francisco VA Health Care System,All,"216 Months and older   (Adult, Older Adult)",Phase 3,300,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20-30517,"April 30, 2020",March 2021,August 2021,"April 27, 2020",NA,"May 11, 2020","San Francisco VA, San Francisco, California, United States",NA,https://ClinicalTrials.gov/show/NCT04363203,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,37,NCT04374019,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,NA,Recruiting,No Results Available,COVID|Sars-CoV2,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate,Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function,Susanne Arnold|University of Kentucky,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-20-COVID-01-PMC,"May 1, 2020",May 2021,May 2021,"May 5, 2020",NA,"May 7, 2020","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",NA,https://ClinicalTrials.gov/show/NCT04374019,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,38,NCT04322396,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,ProPAC-COVID,Recruiting,No Results Available,Virus Diseases|Infection Viral|Corona Virus Infection,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,"Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark",All,"Child, Adult, Older Adult",Phase 2,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KronLungesyg_COVID_19_protokol,"April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",NA,"May 11, 2020","Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark",NA,https://ClinicalTrials.gov/show/NCT04322396,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,39,NCT04344457,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",COVID-19,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product,Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement,"Perseverance Research Center, LLC|Athena Medical Group",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,80,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIZ-PRC-COVID-19,"April 16, 2020","June 20, 2020","September 30, 2020","April 14, 2020",NA,"April 30, 2020","Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States",NA,https://ClinicalTrials.gov/show/NCT04344457,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,40,NCT04344444,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,RCT,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Azithromycin,Most severe outcome,LCMC Health,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID 2020-001,"April 10, 2020","April 10, 2021","December 10, 2021","April 14, 2020",NA,"April 14, 2020","University Medical Center New Orleans, New Orleans, Louisiana, United States",NA,https://ClinicalTrials.gov/show/NCT04344444,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,41,NCT04359095,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020","Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia",NA,https://ClinicalTrials.gov/show/NCT04359095,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,42,NCT04373733,A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,PIONEER,Not yet recruiting,No Results Available,Coronavirus Infection,Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Other: Standard of care management,"Time to improvement by two points on a seven-category ordinal scale|Clinical status on a seven-category ordinal scale (Day 7)|Clinical status on a seven-category ordinal scale (Day 14)|Overall survival|Time to improvement by two points on the NEWS score|Time to improvement by two points on the NEWS element score for temperature|Time to improvement by two points on the NEWS element score for heartrate|Time to improvement by two points on the NEWS element score for respiratory rate|Time to improvement by two points on the NEWS element score for oxygen saturation.|Admission to intensive care|Requirement for mechanical ventilation|Requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen|Incidence of bacterial or fungal infection|Incidence of adverse events not directly caused by COVID-19 infection.","Chelsea and Westminster NHS Foundation Trust|NEAT ID Foundation|FUJIFILM Toyama Chemical Co., Ltd.|Imperial College London|Universitaire Ziekenhuizen Leuven",All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CW002|2020-001449-38,"May 1, 2020","March 31, 2021","March 31, 2021","May 4, 2020",NA,"May 4, 2020","Chelsea and Westminster Hospital, London, United Kingdom|West Middlesex University Hospital, London, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT04373733,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,43,NCT04351919,Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+),COVID+PA,Not yet recruiting,No Results Available,Patients With COVID19,Drug: Hydroxychloroquine|Drug: Azithromycin,improvment or healing of clinical signs|Evolution of clinical signs,Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Dacima Consulting,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ECC2020-04,"May 5, 2020","July 15, 2020","July 15, 2020","April 17, 2020",NA,"May 5, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia",NA,https://ClinicalTrials.gov/show/NCT04351919,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,44,NCT04339816,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,AZIQUINE-ICU,Recruiting,No Results Available,COVID-19|Respiratory Failure,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo,Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90,"Frantisek Duska, MD, PhD|Masaryk Hospital Usti nad Labem|University Hospital Pilsen|The Faculty Hospital Na Bulovce|St. Anne's University Hospital Brno, Czech Republic|University Hospital, Motol|General University Hospital, Prague|University Hospital Olomouc|Charles University, Czech Republic",All,"18 Years and older   (Adult, Older Adult)",Phase 3,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",AZIQUINE-ICU-25032020|2020-001456-18,"May 13, 2020","December 31, 2021","June 30, 2022","April 9, 2020",NA,"June 4, 2020","František Duška, Praha, Česká Republika, Czechia",NA,https://ClinicalTrials.gov/show/NCT04339816,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,45,NCT04341727,"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",WU352,Suspended,No Results Available,Coronavirus Infection,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate,Hours to recovery|Time fever resolution,Washington University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,202003188,"April 4, 2020","April 1, 2021","August 1, 2021","April 10, 2020",NA,"June 4, 2020","Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",NA,https://ClinicalTrials.gov/show/NCT04341727,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,46,NCT04383717,Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial,NA,Not yet recruiting,No Results Available,Respiratory Tract Infections,Drug: Levamisole and isoprinosine|Drug: Azithromycin and hydroxychloroquine,COVID 19 induced fever in both groups|COVID 19 induced dyspnea in both groups|COVID 19 viral load in both groups|laboratory clearance in both groups: CRP in mg/dL,Cairo University,All,"6 Years to 90 Years   (Child, Adult, Older Adult)",Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Levamisole and isoprinosine,"May 5, 2020","August 30, 2020","October 30, 2020","May 12, 2020",NA,"May 13, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04383717,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,47,NCT04411433,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,NA,Recruiting,No Results Available,Sars-CoV2|COVID-19,Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin,"Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oxymetry from baseline|Changes in fever from baseline","Ministry of Health, Turkey|Hacettepe University, Faculty of Medicine|Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization|Umraniye Education and Research Hospital|SB Istanbul Education and Research Hospital|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey|Tepecik Training and Research Hospital|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine|Ankara University|Ankara City Hospital Bilkent|Ankara Training and Research Hospital|Ege University Hospital (Application and Research Center)|Kocaeli Derince Education and Research Hospital|Istanbul University, Istanbul Faculty of Medicine|Kayseri City Hospital",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-19-FAV,"May 8, 2020","July 30, 2020","July 30, 2020","June 2, 2020",NA,"June 2, 2020","Hacettepe University, School of Medicine, Ankara, Turkey",NA,https://ClinicalTrials.gov/show/NCT04411433,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,48,NCT04334512,A Study of Quintuple Therapy to Treat COVID-19 Infection,HAZDpaC,Not yet recruiting,No Results Available,COVID-19|Corona Virus Infection|Coronavirus-19|Sars-CoV2,Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc,The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy,ProgenaBiome,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRG-044,May 2020,May 2021,August 2021,"April 6, 2020",NA,"May 12, 2020","ProgenaBiome, Ventura, California, United States",NA,https://ClinicalTrials.gov/show/NCT04334512,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,49,NCT04368351,Bacteriotherapy in the Treatment of COVID-19,BACT-ovid,"Active, not recruiting",No Results Available,COVID|Pneumonia|Diarrhea,Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine,delta of time of disappearance of acute diarrhea|Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital,University of Roma La Sapienza,All,"18 Years and older   (Adult, Older Adult)",NA,70,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,DPHID-UniRoma05,"March 1, 2020","June 30, 2020","July 31, 2020","April 29, 2020",NA,"May 4, 2020","Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy",NA,https://ClinicalTrials.gov/show/NCT04368351,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,50,NCT04390152,Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,NA,Not yet recruiting,No Results Available,Acute Respiratory Distress Syndrome,"Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)","Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between ""Sequential Organ Failure Assessment"" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.",BioXcellerator|Clinical Somer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,40,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BIOXSOMCOV001,June 2020,November 2020,May 2021,"May 15, 2020",NA,"May 19, 2020","Clinical Somer, Rionegro, Antioquia, Colombia",NA,https://ClinicalTrials.gov/show/NCT04390152,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,51,NCT04363060,Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,AziA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate,Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion,Nantes University Hospital,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,104,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC20_0168,"April 30, 2020","July 30, 2020","July 30, 2020","April 27, 2020",NA,"April 29, 2020","Chu Angers, Angers, France|CHD Vendée, La Roche-sur-Yon, France|CHU Poitiers, Poitiers, France",NA,https://ClinicalTrials.gov/show/NCT04363060,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,52,NCT04350281,Double Therapy With IFN-beta 1b and Hydroxychloroquine,NA,Recruiting,No Results Available,COVID,Drug: Interferon Beta-1B|Drug: Hydroxychloroquine,Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes,The University of Hong Kong,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UW 20-211,"April 9, 2020","March 31, 2022","July 31, 2022","April 17, 2020",NA,"April 17, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",NA,https://ClinicalTrials.gov/show/NCT04350281,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,53,NCT04342221,Hydroxychloroquine for COVID-19,COV-HCQ,Recruiting,No Results Available,"COVID-19, Hydroxychloroquine Sulfate",Drug: Hydroxychloroquine Sulfate|Drug: Placebo,Effect of HCQ on in vivo viral clearance,University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,220,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COV-HCQ|2020-001224-33,"March 29, 2020",March 2021,February 2022,"April 10, 2020",NA,"April 10, 2020","Institute for Tropical Medicine, Tübingen, Germany",NA,https://ClinicalTrials.gov/show/NCT04342221,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,54,NCT04354428,Treatment for COVID-19 in High-Risk Adult Outpatients,NA,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid,Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events,University of Washington|Bill and Melinda Gates Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,630,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STUDY00009878|INV-017062,"April 16, 2020",July 2020,October 2020,"April 21, 2020",NA,"May 28, 2020","Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04354428,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,55,NCT04418193,Patient Preference Trial for COVID-19 (PPT-COVID),PPT-COVID,Recruiting,No Results Available,Coronavirus,NA,"Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the World Health Organisation (WHO) Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) Reverse Transcriptase (RT) - Polymerase Chain Reaction (PCR) on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older",Centre Hospitalier Princesse Grace,All,"18 Years to 99 Years   (Adult, Older Adult)",NA,100,Other,Observational,Observational Model: Cohort|Time Perspective: Other,20-08,"April 6, 2020","September 1, 2020","September 1, 2020","June 5, 2020",NA,"June 9, 2020","Centre Hospitalier Princesse Grace, Monaco, Monaco",NA,https://ClinicalTrials.gov/show/NCT04418193,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,56,NCT04343092,Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,NA,Completed,No Results Available,COVID 19,Drug: Ivermectin (IVM),Number of cured patients|Mean time to cure of the covid 19 patients,University of Baghdad,All,"18 Years and older   (Adult, Older Adult)",Phase 1,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRO20040001,"April 18, 2020","May 31, 2020","June 1, 2020","April 13, 2020",NA,"June 5, 2020","General Directorate of Medical City, Bagdad, Baghdad, Iraq",NA,https://ClinicalTrials.gov/show/NCT04343092,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,57,NCT04365582,OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,OUTCOV,Not yet recruiting,No Results Available,COVID,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab,Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events,Groupe Hospitalier Paris Saint Joseph,All,"50 Years and older   (Adult, Older Adult)",Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OUTCOV,"April 28, 2020","July 28, 2020","January 28, 2021","April 28, 2020",NA,"April 28, 2020","Hôpital Privé d'Antony, Antony, France|Hôpital Avicenne, Bobigny, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Institut Mutualiste Montsouris, Paris, France",NA,https://ClinicalTrials.gov/show/NCT04365582,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,58,NCT04353245,Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System,PostCOVID19,Not yet recruiting,No Results Available,COVID19|Corona Virus Infection|Myocardial Injury|Pneumonia,Other: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM,Fibrosis|Ergospirometers,University of Sao Paulo General Hospital,All,"18 Years and older   (Adult, Older Adult)",NA,130,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,UAP107,"June 1, 2020","September 30, 2021","September 30, 2021","April 20, 2020",NA,"April 20, 2020","Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",NA,https://ClinicalTrials.gov/show/NCT04353245,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,59,NCT04366089,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,PROBIOZOVID,Recruiting,No Results Available,"COVID|SARS-CoV 2|Pneumonia, Viral|Coronavirus Infection","Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine",Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital|delta in the value of interleukin (IL)-1|delta in the value of IL-6|delta in the value of IL-10|delta in the value of Tumor Necrosis Factor (TNF)-alpha|delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)|delta in the value of CD8+ CD38/ HLA-DR|delta in the value of fecal calprotectin|delta in the value of lipopolysaccharide (LPS)|delta in the value of zonulin|delta in the value of alpha1-antitrypsin,"Roberto Poscia MD, PhD|Azienda Policlinico Umberto I",All,"18 Years and older   (Adult, Older Adult)",Phase 2,152,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,110/2020,"March 26, 2020","October 30, 2020","December 31, 2020","April 28, 2020",NA,"April 28, 2020","Francesco Pugliese, Rome, RM, Italy",NA,https://ClinicalTrials.gov/show/NCT04366089,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,60,NCT04381936,Randomised Evaluation of COVID-19 Therapy,RECOVERY,Recruiting,No Results Available,Severe Acute Respiratory Syndrome,Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab,All-cause mortality|Duration of hospital stay|Need for (and duration of) ventilation|Composite endpoint of death or need for mechanical ventilation or ECMO,"University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Clinical Trials Unit Support Funding",All,"Child, Adult, Older Adult",Phase 2|Phase 3,12000,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NDPHRECOVERY|2020-001113-21|ISRCTN50189673,"March 19, 2020",December 2020,June 2021,"May 11, 2020",NA,"June 5, 2020","Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT04381936,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,61,NCT04324463,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,ACT COVID19,Recruiting,No Results Available,Coronavirus|Severe Acute Respiratory Syndrome,Drug: Azithromycin|Drug: Hydoxychloroquine or Chloroquine|Drug: Interferon-Beta,Outpatients: Hospital Admission or Death|Inpatients: Invasive mechanical ventilation or mortality,Population Health Research Institute|Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHRI.ACT.COVID19,"April 21, 2020","September 30, 2020","December 31, 2020","March 27, 2020",NA,"April 24, 2020","Hamilton Health Sciences, Hamilton, Ontario, Canada",NA,https://ClinicalTrials.gov/show/NCT04324463,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,62,NCT04398004,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,ACHIEVE,Recruiting,No Results Available,COVID-19|Virus Diseases|Corona Virus Infection,Drug: Clarithromycin,"Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8",Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ACHIEVE|2020-001882-36,"May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",NA,"May 26, 2020","COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece",NA,https://ClinicalTrials.gov/show/NCT04398004,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-hcq-azithromycin.csv,63,NCT04323345,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,NA,Recruiting,No Results Available,COVID-19,Dietary Supplement: Natural Honey|Other: Standard Care,Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results,Misr University for Science and Technology,All,"5 Years to 75 Years   (Child, Adult, Older Adult)",Phase 3,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,MUST23032020,"April 15, 2020","December 15, 2020","January 15, 2021","March 26, 2020",NA,"April 21, 2020","Mahmoud Tantawy, Cairo, Egypt",NA,https://ClinicalTrials.gov/show/NCT04323345,HCQ + Azithromycin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,1,NCT04343092,Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,NA,Completed,No Results Available,COVID 19,Drug: Ivermectin (IVM),Number of cured patients|Mean time to cure of the covid 19 patients,University of Baghdad,All,"18 Years and older   (Adult, Older Adult)",Phase 1,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRO20040001,"April 18, 2020","May 31, 2020","June 1, 2020","April 13, 2020",NA,"June 5, 2020","General Directorate of Medical City, Bagdad, Baghdad, Iraq",NA,https://ClinicalTrials.gov/show/NCT04343092,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,2,NCT04373824,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,NA,Recruiting,No Results Available,COVID,Drug: Ivermectin,effect of Ivermectin on eradication of virus.,Max Healthcare Insititute Limited,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MHC-COVID-19- INV- ACT-BHR,"April 25, 2020","July 25, 2020","July 25, 2020","May 4, 2020",NA,"May 4, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",NA,https://ClinicalTrials.gov/show/NCT04373824,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,3,NCT04392713,Efficacy of Ivermectin in COVID-19,NA,Recruiting,No Results Available,COVID,Drug: Ivermectin 6 MG Oral Tablet (2 tablets),Negative PCR|Need for mechanical ventilation,"Combined Military Hospital, Pakistan",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IVE-COV,"April 15, 2020",July 2020,July 2020,"May 19, 2020",NA,"May 19, 2020","Combined Military Hospital Lahore, Lahore, Punjab, Pakistan",NA,https://ClinicalTrials.gov/show/NCT04392713,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,4,NCT04403555,Ivermectin and Doxycycine in COVID-19 Treatment,NA,Not yet recruiting,No Results Available,COVID,Drug: Ivermectin|Drug: Doxycycline|Drug: Chloroquine,The number of patients with resolved viral infection,Tanta University,All,"Child, Adult, Older Adult",Phase 2|Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,tanta combo covid treatment,"June 1, 2020","December 1, 2030","December 3, 2030","May 27, 2020",NA,"May 27, 2020","Sherief Abd-Elsalam, Tanta, Egypt",NA,https://ClinicalTrials.gov/show/NCT04403555,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,5,NCT04422561,Prophylactic Ivermectin in COVID-19 Contacts,NA,Recruiting,No Results Available,COVID,Drug: Ivermectin Tablets,"appearance of symptoms ( fever ,cough, sore throat, myalgia,diarrhea, shortness of breath)|development of COVID",Zagazig University,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ZU-IRB#6150l31-5-2020,"May 31, 2020",June 2020,July 2020,"June 9, 2020",NA,"June 9, 2020","Zagazig University, Zagazig, Sharkia, Egypt",NA,https://ClinicalTrials.gov/show/NCT04422561,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,6,NCT04351347,The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,NA,Not yet recruiting,No Results Available,COVID,Drug: Chloroquine|Drug: Nitazoxanide|Drug: Ivermectin,Number of patients with virological cure,Tanta University,All,"Child, Adult, Older Adult",Phase 2|Phase 3,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ivermecin covid,"April 17, 2020","December 1, 2030","December 1, 2030","April 17, 2020",NA,"April 17, 2020","Tanta University, Tanta, Egypt",NA,https://ClinicalTrials.gov/show/NCT04351347,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,7,NCT04399746,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,IvAzCol,Recruiting,No Results Available,COVID,Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol,Viral clearance|Symptoms duration|SpO2|SpO2/FiO2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IvAzCol,"March 15, 2020","May 20, 2020","June 10, 2020","May 22, 2020",NA,"May 22, 2020","Outpatient treatment, Mexico City, Mexico",NA,https://ClinicalTrials.gov/show/NCT04399746,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,8,NCT04381884,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,NA,Recruiting,No Results Available,COVID-19 Drug Treatment,Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.,Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2,Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de Investigación Veterinaria Tandil CIVETAN|Hospital de Pediatría Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,45,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IVM-AR-1,"May 18, 2020","June 30, 2020","June 30, 2020","May 11, 2020",NA,"May 27, 2020","Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina",NA,https://ClinicalTrials.gov/show/NCT04381884,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,9,NCT04360356,Ivermectin and Nitazoxanide Combination Therapy for COVID-19,NA,Not yet recruiting,No Results Available,COVID-19,Combination Product: Ivermectin plus Nitazoxanide|Other: Standard Care,"Number of Patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients",Tanta University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IVR/NTZ,May 2020,October 2020,December 2020,"April 24, 2020",NA,"April 24, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04360356,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,10,NCT04374279,Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy,RECOVER,Not yet recruiting,No Results Available,COVID-19|SARS-CoV 2,Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Ivermectin 3Mg Tab,Number of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV2003|IRB00249425,June 2020,June 2021,June 2021,"May 5, 2020",NA,"May 5, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",NA,https://ClinicalTrials.gov/show/NCT04374279,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,11,NCT04392427,New Antiviral Drugs for Treatment of COVID-19,NA,Not yet recruiting,No Results Available,COVID|Drug Effect,"Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :",negative test result for COVID-19,Mansoura University,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,100,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,20.05.69,May 2020,May 2022,May 2022,"May 18, 2020",NA,"May 18, 2020","Mansoura University, Mansoura, Select A State Or Province, Egypt",NA,https://ClinicalTrials.gov/show/NCT04392427,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,12,NCT04391127,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,NA,Recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo,"Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization",Centenario Hospital Miguel Hidalgo,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",Phase 3,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2020-A-09,"May 4, 2020","August 30, 2020","September 30, 2020","May 18, 2020",NA,"May 27, 2020","Jose Manuel Arreola Guerra, Aguascalientes, Mexico",NA,https://ClinicalTrials.gov/show/NCT04391127,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,13,NCT04405843,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Ivermectin Oral Product|Drug: Placebo,Time to event|Clinical condition on day 2|Clinical condition on day 5|Clinical condition on day 8|Clinical condition on day 11|Clinical condition on day 15|Clinical condition on day 21|Proportion of subjects with additional care|Proportion of subjects who die|Duration of additional care|Adverse events|Proportion of subjects who discontinue intervention,Centro de Estudios en Infectogía Pediatrica,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,400,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ScDi823,June 2020,October 2020,"November 1, 2020","May 28, 2020",NA,"May 28, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04405843,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,14,NCT04407130,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,NA,Not yet recruiting,No Results Available,COVID-19 Patients,Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo,Virological clearance|Remission of fever|Remission of cough|Patients requiring oxygen|Patients failing to maintain SpO2 >88% despite oxygenation|Number of days on oxygen support|Chest X-ray improvement|Duration of hospitalization|All causes of mortality,"International Centre for Diarrhoeal Disease Research, Bangladesh",All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 2,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PR-20039,June 2020,July 2020,July 2020,"May 29, 2020",NA,"June 9, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04407130,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,15,NCT04390022,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,SAINT,Recruiting,No Results Available,Covid-19|Coronavirus Infection|SARS-CoV-2 Infection,Drug: Ivermectin|Drug: Placebo,"Proportion of patients with a positive SARS-CoV-2 PCR|Mean viral load|Fever and cough progression|Seroconversion at day 21|Proportion of drug-related adverse events|Levels of IgG, IgM and IgA|Frequency of innate immune cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells|Results from cytokine Human Magnetic 30-Plex Panel","Clinica Universidad de Navarra, Universidad de Navarra|Barcelona Institute for Global Health",All,18 Years to 59 Years   (Adult),Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SAINT,"May 14, 2020","August 4, 2020","August 30, 2020","May 15, 2020",NA,"May 21, 2020","Clinica Universidad de Navarra, Pamplona, Navarra, Spain",NA,https://ClinicalTrials.gov/show/NCT04390022,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,16,NCT04407507,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms",SILVERBULLET,Not yet recruiting,No Results Available,COVID-19,Drug: Ivermectin|Drug: Placebo,Participants with a disease control status defined as no disease progression to severe.,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,SARS-COV-IverMX-01,June 2020,August 2020,October 2020,"May 29, 2020",NA,"May 29, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04407507,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,17,NCT04382846,Novel Regimens in COVID-19 Treatment,NA,Not yet recruiting,No Results Available,COVID|Corona Virus Infection,Drug: Nitazoxanide|Drug: Ivermectin|Drug: Chloroquine|Drug: Azithromycin,Number of patients with virological cure,Tanta University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,tanta covid treatment,"May 8, 2020","December 1, 2030","December 1, 2030","May 11, 2020",NA,"May 11, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04382846,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,18,NCT04374019,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,NA,Recruiting,No Results Available,COVID|Sars-CoV2,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate,Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function,Susanne Arnold|University of Kentucky,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-20-COVID-01-PMC,"May 1, 2020",May 2021,May 2021,"May 5, 2020",NA,"May 7, 2020","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",NA,https://ClinicalTrials.gov/show/NCT04374019,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-ivermectin.csv,19,NCT04345419,A Real-life Experience on Treatment of Patients With COVID 19,NA,Not yet recruiting,No Results Available,COVID,Drug: Chloroquine|Drug: Favipiravir|Drug: Nitazoxanide|Drug: Ivermectin|Drug: Niclosamide|Drug: Other drugs,Number of patients with decreased viral load,Tanta University,All,"Child, Adult, Older Adult",Phase 2|Phase 3,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,COVID 19 treatment,"April 30, 2020",December 2029,December 2029,"April 14, 2020",NA,"April 29, 2020","Tanta university hospital, Tanta, Egypt",NA,https://ClinicalTrials.gov/show/NCT04345419,Ivermectin
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,1,NCT04365725,"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections",REMDECO-19,Recruiting,No Results Available,COVID-19,Drug: Remdesivir,Clinical course on Day 15.|Clinical course on Day 3.|Clinical course on Day 8|Clinical course on Day 11.|Clinical course on Day 29.|Duration of treatment|Sepsis-related Organ Failure Assessment score|Duration without mechanical ventilation|Mortality|cumulative incidence of grade 3 and 4 adverse events (AEs).,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",NA,200,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,APHP200522,"May 5, 2020",June 2020,June 2020,"April 28, 2020",NA,"May 13, 2020","Hôpital Cochin, Paris, France",NA,https://ClinicalTrials.gov/show/NCT04365725,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,2,NCT04410354,Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir,"Number of subjects not hospitalized or, if hospitalized, free of respiratory failure|Adverse Events|National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale|Temperature|Death|Mechanical ventilation|Vasopressor Support|Oxygen Therapy|Cessation of Viral Shedding|Change in Oxygen Saturation/Fraction of Inspired Oxygen","ViralClear Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",VC-02-01,June 2020,July 2020,August 2020,"June 1, 2020",NA,"June 2, 2020","Mayo Clinic in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States",NA,https://ClinicalTrials.gov/show/NCT04410354,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,3,NCT04292899,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,6000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5773|2020-000841-15,"March 6, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT04292899,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,4,NCT04252664,A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,NA,Suspended,No Results Available,COVID-19|SARS-CoV-2,Drug: Remdesivir|Drug: Remdesivir placebo,"Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events",Capital Medical University|Chinese Academy of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 3,308,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAP-China remdesivir 1,"February 12, 2020","April 10, 2020","April 27, 2020","February 5, 2020",NA,"April 15, 2020","Jin Yin-tan hospital, Wuhan, Hubei, China",NA,https://ClinicalTrials.gov/show/NCT04252664,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,5,NCT04292730,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NA,"Active, not recruiting",No Results Available,COVID-19,Drug: Remdesivir|Drug: Standard of Care,The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-540-5774|2020-000842-32,"March 15, 2020",June 2020,June 2020,"March 3, 2020",NA,"June 2, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT04292730,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,6,NCT04409262,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020","eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Michael'S Medical Center, Newark, New Jersey, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States",NA,https://ClinicalTrials.gov/show/NCT04409262,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,7,NCT04257656,A Trial of Remdesivir in Adults With Severe COVID-19,NA,Terminated,No Results Available,COVID-19|Remdesivir|SARS-CoV-2,Drug: Remdesivir|Drug: Remdesivir placebo,Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events,Capital Medical University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,237,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAP-China remdesivir 2,"February 6, 2020","March 30, 2020","April 10, 2020","February 6, 2020",NA,"April 15, 2020","Bin Cao, Beijing, Beijing, China",NA,https://ClinicalTrials.gov/show/NCT04257656,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,8,NCT04323761,Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NA,Available,No Results Available,SARS-CoV2 Infection,Drug: Remdesivir,NA,Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",NA,NA,Industry,Expanded Access:Treatment IND/Protocol,NA,GS-US-540-5821|2020-001453-49,NA,NA,NA,"March 27, 2020",NA,"June 9, 2020","University of Alabama- Birmingham, Birmingham, Alabama, United States|Banner- University Medical Center Phoenix, Phoenix, Arizona, United States|Community Regional Medical Centers (CRMC), Fresno, California, United States|St. Jude Medical Center, Fullerton, California, United States|Scripps Memorial Hospital La Jolla, La Jolla, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Huntington Hospital, Pasadena, California, United States|Scripps Mercy Hospital, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California, Medical Center (Parnassus Campus), San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|San Mateo Medical Center, San Mateo, California, United States|Santa Rosa Memorial Hospital, Santa Rosa, California, United States|Los Robles Regional Medical Center, Thousand Oaks, California, United States|PIH Health Whittier Hospital, Whittier, California, United States|The Medical Center Of Aurora, Aurora, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Middlesex Health, Middletown, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|The Stamford Health Medical Group- Pulmonary Associates, Stamford, Connecticut, United States|George Washington University Hospital, Washington, District of Columbia, United States|Aventura Hospital and Medical Center, Aventura, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States|Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Swedish Hospital, Chicago, Illinois, United States|Mercy Hospital & Medical Center, Chicago, Illinois, United States|Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States|St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States|Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States|Riverview Health, Noblesville, Indiana, United States|Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States|Touro Infirmary, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Slidell Memorial Hospital, Slidell, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Calvert Health Medical Center, Prince Frederick, Maryland, United States|University of Maryland St. Joseph Medical Center, Towson, Maryland, United States|Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Charlton Memorial Hospital, Fall River, Massachusetts, United States|Lawrence General Hospital, Lawrence, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Huron Valley-Sinai Hospital, Commerce, Michigan, United States|Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|McLaren Health Care Corporation, Flint, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States|Clara Maass Medical Center, Belleville, New Jersey, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|Trinitas Regional Medical Center, Elizabeth, New Jersey, United States|Englewood Health, Englewood, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|CentraState Medical Center, Freehold, New Jersey, United States|Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States|Jersey City Medical Center, Jersey City, New Jersey, United States|Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Ocean Medical Center, Oakhurst, New Jersey, United States|Bayshore Medical Center, Red Bank, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Capital Health, Trenton, New Jersey, United States|Virtua Health Voorhees Campus, Voorhees, New Jersey, United States|St. Peter's Hospital, Albany, New York, United States|Mount Sinai Queens, Astoria, New York, United States|Good Samaritan Hospital Medical Center, Bay Shore, New York, United States|Southside Hospital, Bay Shore, New York, United States|Lincoln Medical Center, Bronx, New York, United States|St Barnabus Hospital, Bronx, New York, United States|Montefiore Medical Center, Weiler Campus, Bronx, New York, United States|Montefiore Health System Moses Medical Center, Bronx, New York, United States|The Brooklyn Hospital Center, Brooklyn, New York, United States|Kingsbrook Jewish Medical Center, Brooklyn, New York, United States|University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States|Woodhull Medical Center, Brooklyn, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|New York Harbor VA Medical Center, Brooklyn, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Interfaith Medical Center, Brooklyn, New York, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Mount Sinai Brooklyn, Brooklyn, New York, United States|New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States|Kaleida Health System, Buffalo, New York, United States|Nassau University Medical Center, East Meadow, New York, United States|New York Presbyterian- Queens, Flushing, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Queens Hospital Center, Jamaica, New York, United States|NYU Langone Health, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States|NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States|New York City Health + Hospitals / Harlem, New York, New York, United States|New York Presbyterian Lower Manhattan Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Rochester General Hospital, Rochester, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Ellis Hospital, Schenectady, New York, United States|Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States|Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States|Samaritan Hospital, Troy, New York, United States|UNC Hospitals, Chapel Hill, North Carolina, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|The Ohio State University College of Medicine, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Saint Francis Hospital, Tulsa, Oklahoma, United States|St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States|Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Roger Williams Medical Center,, Providence, Rhode Island, United States|Kent Hospital, Warwick, Rhode Island, United States|St. Francis Hospital, Greenville, South Carolina, United States|Lexington Medical Center, West Columbia, South Carolina, United States|TriStar Centennial Medical Center, Nashville, Tennessee, United States|St. David's South Austin Medical Center, Austin, Texas, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|HCA Houston Healthcare West, Houston, Texas, United States|University of Texas Medical Branch Galveston, League City, Texas, United States|Covenant Medical Center, Lubbock, Texas, United States|Methodist Mansfield Medical Center, Mansfield, Texas, United States|Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States|Saint Mark's Hospital, Salt Lake City, Utah, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Henrico Doctors Hospital, Richmond, Virginia, United States|Carilion Medical Center, Roanoke, Virginia, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Universitätsklinik für Innere Medizin II, Innsbruck, Austria|Kepler Universitätsklinikum, Linz, Austria|Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria|Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium|Ghent University Hospital, Ghent, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Hôpital Civil Marie Curie, Lodelinsart, Belgium|William Osler Health System, Brampton, Ontario, Canada|The Ottowa Hospital, Ottawa, Ontario, Canada|Nicosia General Hospital, Nicosia, Cyprus|Všeobecná fakultní nemocnice v Praze, Prague, Czechia|Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia|Nemocnice Na Bulovce, Praha 8, Czechia|Rigshospitalet, Copenhagen, Denmark|Põhja-Eesti Regionaalhaigla, Tallinn, Estonia|Vilnius University, Tartu, Estonia|Hopital Avicenne, Bobigny, France|Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France|Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France|Hôpitaux Civils de Colmar, Colmar, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|Hôpital Raymond Poincaré, Garches, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Hôpital Charles-Nicolle, Rouen, France|Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitatsklinikum, Essen, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Caritas-Krankenhaus St. Josef, Regensburg, Germany|Klinikum Würzburg Mitte, Würzburg, Germany|University General Hospital of Patras Panagia I Voithia, Patra, Greece|General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece|Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary|Landspítali, Reykjavik, Iceland|Kerry University Hospital, Tralee, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|Hasharon Hospital, Petah Tikva, Israel|Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy|Azienda Ospedaliero Universitaria, Bologna, Italy|Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy|Azienda Ospedaliero - Universitaria Careggi, Florence, Italy|Ospedale Policlinico San Martino, Genova, Italy|Ospedale San Gerardo di Monza, Monza, Italy|Azienda Ospedaliera dei Colli, Napoli, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Azienda Ospedaliero Universitaria, Turin, Italy|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|HagaZiekenhuis, The Hague, Netherlands|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego, Lodz, Poland|Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland|Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland|Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal|Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal|Centro Hospitalar Universitário De São João, Porto, Portugal|Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania|Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania|Clinical hospital for infectious disease, Timisoara, Romania|Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia|Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia|Univerzitetni Klinicni Center Maribor, Maribor, Slovenia|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Donostia, San Sebastian, Spain|Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain|Hospital Virgen De La Salud, Toledo, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Kantonsspital Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Spitalzentrum Biel, Biel, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|St. George's Hospital, London, United Kingdom|Southampton University Hospital, Southampton, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT04323761,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,9,NCT04401579,Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1032,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006 ACTT-II,"May 8, 2020","August 1, 2023","August 1, 2023","May 26, 2020",NA,"June 9, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore",NA,https://ClinicalTrials.gov/show/NCT04401579,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,10,NCT04280705,Adaptive COVID-19 Treatment Trial (ACTT),NA,Recruiting,No Results Available,COVID-19,Other: Placebo|Drug: Remdesivir,"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first",National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,800,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20-0006,"February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",NA,"May 7, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT04280705,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,11,NCT04330690,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,CATCO,Recruiting,No Results Available,COVID-19,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir,Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs),Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2114,"March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",NA,"June 5, 2020","Peter Lougheed Centre, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|University of Alberta Hopsital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada|Island Health - Victoria General Hospital, Victoria, British Columbia, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|St.Joseph's Health Care, London, Ontario, Canada|University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Hôpital Montfort, Ottawa, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",NA,https://ClinicalTrials.gov/show/NCT04330690,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,12,NCT04321616,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,NA,Recruiting,No Results Available,SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS,Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC,In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction,Oslo University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,700,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,118684,"March 28, 2020",August 2020,November 2020,"March 25, 2020",NA,"April 14, 2020","Andreas Barratt-Due, Oslo, Norway",NA,https://ClinicalTrials.gov/show/NCT04321616,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,13,NCT04302766,Expanded Access Remdesivir (RDV; GS-5734™),NA,Available,No Results Available,Coronavirus Disease 2019,Drug: Remdesivir,NA,U.S. Army Medical Research and Development Command,All,"Child, Adult, Older Adult",NA,NA,U.S. Fed,Expanded Access:Intermediate-size Population|Treatment IND/Protocol,NA,S-20-01,NA,NA,NA,"March 10, 2020",NA,"April 10, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04302766,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,14,NCT04315948,Trial of Treatments for COVID-19 in Hospitalized Adults,DisCoVeRy,Recruiting,No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-15,"March 22, 2020",March 2023,March 2023,"March 20, 2020",NA,"June 5, 2020","Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France|Centre Hospitalier Régional Universitaire de Besançon, Besançon, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|APHP - hôpital Henri-Mondor, Créteil, France|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France|Centre Hospitalier Universitaire de Martinique, Fort De France, France|AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Hospices Civils de Lyon, Lyon, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France|Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalo-Universitaire de Nice, Nice, France|APHP - Hôpital Saint Antoine, Paris, France|APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France|APHP - Hôpital Cochin, Paris, France|Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France|APHP- Hôpital Européen Georges-Pompidou, Paris, France|APHP - Hôpital Bichat Claude Bernard, Paris, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Hopital DELAFONTAINE, Saint-Denis, France|Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France|Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier de Tourcoing, Tourcoing, France|Centre Hospitalier Universitaire de Tours, Tours, France|Centre Hospitalier Annecy Genevois, Épagny, France|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg|Hôpitaux Robert Schuman, Luxembourg, Luxembourg",NA,https://ClinicalTrials.gov/show/NCT04315948,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,15,NCT04359901,Sarilumab for Patients With Moderate COVID-19 Disease,NA,Recruiting,No Results Available,COVID,Biological: SARILUMAB,Intubation or death,Westyn Branch-Elliman|VA Boston Healthcare System,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 3305,"April 10, 2020",April 2022,April 2023,"April 24, 2020",NA,"June 4, 2020","VA Boston Healthcare System, Boston, Massachusetts, United States",NA,https://ClinicalTrials.gov/show/NCT04359901,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,16,NCT04405310,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,CPC-SARS,Recruiting,No Results Available,COVID-19,Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine),Death|Lenth of stay ICU|Days of Mechanical Ventilation|Suplemental Oxigen support|Viral Load by RT-PCR|Inflamatory biomarkers|SOFA (sequencial Organ Failure Assesment),"Grupo Mexicano para el Estudio de la Medicina Intensiva|Hospital General Naval de Alta Especialidad - Escuela Medico Naval|National Institute of Pediatrics, Mexico|Instituto Nacional de Enfermedades Respiratorias",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",DI/20/201/04/19,"May 20, 2020","June 20, 2020","July 20, 2020","May 28, 2020",NA,"May 28, 2020","Hospital Nava de Alta Especialidad, Mexico City, Mexico|Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico",NA,https://ClinicalTrials.gov/show/NCT04405310,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,17,NCT04359095,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020","Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia",NA,https://ClinicalTrials.gov/show/NCT04359095,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,18,NCT04373044,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",NA,Recruiting,No Results Available,Symptomatic COVID-19 Infection Laboratory-Confirmed,Drug: Baricitinib|Drug: Hydroxychloroquine|Drug: Placebo Administration,Proportion of patients requiring invasive mechanical ventilation or dying|Identification of clinical features (vitals signs - body temperature)|Identification of clinical features (vital signs - respiratory rate)|Identification of clinical features (vital signs - heart rate)|Identification of clinical features (vital signs - blood pressure)|Identification of clinical features (Imaging)|Identification of clinical features (Lab - White Blood Count)|Identification of clinical features (Lab - Absolute Lymphocyte Count)|Identification of clinical features (Lab - Hemoglobin)|Identification of clinical features (Lab - Creatinine)|Identification of biomarkers (C-reactive protein)|Identification of biomarkers (Interleukin-6)|Identification of biomarkers (Tumor Necrosis Factor-alpha)|Identification of adverse events,University of Southern California|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,144,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0S-20-3|NCI-2020-02685|P30CA014089,"May 1, 2020","May 1, 2021","May 1, 2022","May 4, 2020",NA,"June 2, 2020","Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States",NA,https://ClinicalTrials.gov/show/NCT04373044,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,19,NCT04365764,Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NA,Recruiting,No Results Available,Covid-19|ARDS|Pneumonia,NA,Composite of death and mechanical ventilation|Death|Mechanical ventilation|World Health Organization score,Groupe Hospitalier Pitie-Salpetriere|Centre Hospitalier Intercommunal Robert Ballanger|Centre Hospitalier Intercommunal Montfermeil-Le Raincy|CMC Ambroise Paré,All,"Child, Adult, Older Adult",NA,400,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,CIC1421-20-06,"March 14, 2020","May 31, 2020","December 31, 2020","April 28, 2020",NA,"May 20, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France",NA,https://ClinicalTrials.gov/show/NCT04365764,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,20,NCT04356417,Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse,TRAPSAH,Not yet recruiting,No Results Available,"AMD, ACEi's/ARB Prevent/Worsen Risk of COVID-19 Infection",Other: - Synthetic anti-malarial drugs,Identification of serious COVID-19 infections|Pneumonia infections|ICU stay|Oro-tracheal intubation|Death,Assistance Publique - Hôpitaux de Paris|GIS EPI-PHARE,All,"18 Years and older   (Adult, Older Adult)",NA,6000000,Other,Observational,Observational Model: Cohort|Time Perspective: Other,APHP200412,April 2020,June 2020,June 2020,"April 22, 2020",NA,"April 22, 2020","Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France",NA,https://ClinicalTrials.gov/show/NCT04356417,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,21,NCT04401475,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With Moderate to Severe COVID-19 Pneumonia",NA,Not yet recruiting,No Results Available,COVID-19|ARDS,Biological: SOC plus 15mg/kg EB05 IV|Other: SOC plus Placebo IV,"An improvement of two points on the seven-point ordinal scale|Time to clinical improvement by 2 points on the seven-point ordinal scale described in primary outcome.|Ventilator-free days.|Duration of ventilation|Mortality rate|Duration of hospitalization|Time to independence from supplementary oxygen therapy|Time to normalization of oxygen saturation, defined as Sp02 > 94% sustained minimum 24 hours|Change in four-point Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized|Radiological response to treatment based on Thoracic Computerized Tomography Scan (CT-Scan) or Chest X-Ray|Change in cytokines, including IL-6, and C-reactive protein (CRP) levels|Time to resolution of fever for at least 48 hours without antipyretics|Decision by the attending physician to initiate treatment with another targeted immunomodulator (i.e. IL-6 inhibitors)|Change in the four-point Berlin ARDS severity scale|Change in three-point Acute Kidney Injury Network (AKIN) classification|Change in troponin levels",Edesa Biotech Inc.|JSS Medical Research Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,865,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EB05-01-2020,August 2020,February 2021,April 2021,"May 26, 2020",NA,"June 2, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04401475,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,22,NCT04359667,Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,UHID-COVID19,Not yet recruiting,No Results Available,COVID-19|Severe Pneumonia,Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA],serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab,"University Hospital for Infectious Diseases, Croatia",All,"18 Years and older   (Adult, Older Adult)",NA,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,UHID-04,"June 16, 2020","April 16, 2021","May 15, 2021","April 24, 2020",NA,"June 9, 2020","University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",NA,https://ClinicalTrials.gov/show/NCT04359667,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,23,NCT04386447,Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,OsCOVID19,Not yet recruiting,No Results Available,Covid-19|Corona Virus Infection|SARS-CoV 2,Drug: Oxytocin|Drug: Standard of Care,Proportion of cases who during 14 exhibit one of the following conditions|Mortality 28 days after randomization,Azienda Ospedaliero-Universitaria di Parma|University of Parma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,145,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OsCOVID19,"June 3, 2020","October 31, 2020","December 31, 2020","May 13, 2020",NA,"May 19, 2020","CNRS, Lyon, France|Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy|Ospedale San Francesco, Nuoro, Italy",NA,https://ClinicalTrials.gov/show/NCT04386447,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,24,NCT04403477,Convalescent Plasma Therapy in Severe COVID-19 Infection,NA,Recruiting,No Results Available,Covid19|Convalescence,Biological: Convalescent plasma,Proportion of In-hospital mortality|Time to death|Fever|Respiratory distress|Saturation of oxygen|Blood pressure|Oxygen requirement|C-reactive Protein|Ferritin|SGPT|SGOT|ICU stay|Ventilator support|Hospital stay|Proportion of Transfusion reaction,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|Dhaka Medical College",All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BSMMU/2020/6104,"May 20, 2020","July 20, 2020","October 30, 2020","May 27, 2020",NA,"May 27, 2020","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,https://ClinicalTrials.gov/show/NCT04403477,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,25,NCT04395170,Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients,NA,Not yet recruiting,No Results Available,Coronavirus Disease 2019 (COVID-19),Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard (specific) therapy for COVID-19,Admission to ICU and/or mechanical ventilation|Length of hospital stay|Neutralizing antibody (IgG) titers against COVID-19|Safety - Adverse events|Death,"Lifefactors Zona Franca, SAS",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,75,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LFCOLCOVID-19-001,June 2020,December 2020,June 2021,"May 20, 2020",NA,"June 9, 2020","LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia",NA,https://ClinicalTrials.gov/show/NCT04395170,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,26,NCT04361461,Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),NA,Not yet recruiting,No Results Available,Coronavirus Infections|SARS-CoV 2|SARS (Severe Acute Respiratory Syndrome)|Pulmonary Disease,Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin,Individual response rate|All-cause mortality|Duration of mechanical ventilation|Proportion of patients which needed mechanical ventilation during study|World Health Organization (WHO) Ordinal scale|Duration of hospitalization|Rates of drug discontinuation,Apsen Farmaceutica S.A.|Hospital São Paulo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APS001/2020,"May 4, 2020","November 4, 2020","November 4, 2020","April 24, 2020",NA,"April 24, 2020","Apsen Farmacêutica S.A., São Paulo, Brazil",NA,https://ClinicalTrials.gov/show/NCT04361461,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,27,NCT04374071,Early Short Course Corticosteroids in COVID-19,NA,Completed,No Results Available,"COVID|Pneumonia, Viral",Drug: Methylprednisolone,Transfer to Intensive care unit (ICU)|Need for Mechanical Ventilation|Mortality|Development and Severity of ARDS|Length of hospital stay (LOS).,Henry Ford Health System,All,"18 Years and older   (Adult, Older Adult)",NA,250,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,HFH IRB # 13739,"March 12, 2020","March 27, 2020","April 30, 2020","May 5, 2020",NA,"May 5, 2020","Henry Ford Hospital, Detroit, Michigan, United States",NA,https://ClinicalTrials.gov/show/NCT04374071,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,28,NCT04349410,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,FMTVDM,Enrolling by invitation,No Results Available,CoVid 19 Positive,"Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum",Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status,The Camelot Foundation,All,"Child, Adult, Older Adult",Phase 2|Phase 3,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,FMTVDM2020,"April 11, 2020","October 11, 2020","November 11, 2020","April 16, 2020",NA,"April 17, 2020","FHHI-OI-Camelot; QME, Los Angeles, California, United States",NA,https://ClinicalTrials.gov/show/NCT04349410,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,29,NCT04404608,Etiology of Lymphopenia in Covid19 Infection,NA,Not yet recruiting,No Results Available,Lymphopenia,"Diagnostic Test: Complete blood picture, bone marrow aspiration cytology",Death or recovery,Dr Medhat Khafagy|Cairo University,All,"Child, Adult, Older Adult",NA,90,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,201920008.2,June 2020,June 2021,December 2021,"May 27, 2020",NA,"May 27, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04404608,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,30,NCT04335123,Study of Open Label Losartan in COVID-19,NA,Recruiting,No Results Available,COVID-19,Drug: Losartan,"Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg",University of Kansas Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00145514,"March 25, 2020",September 2020,October 2020,"April 6, 2020",NA,"April 24, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",NA,https://ClinicalTrials.gov/show/NCT04335123,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-remdesivir.csv,31,NCT04334460,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NA,Recruiting,No Results Available,Sars-CoV2,Drug: BLD-2660,Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs),Blade Therapeutics|Clinipace Worldwide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B-2660-204,"May 4, 2020",August 2020,September 2020,"April 6, 2020",NA,"May 21, 2020","Blade Research Site, Irvine, California, United States|Blade Research Site, Los Angeles, California, United States|Blade Reseach Site, San Jose, California, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Tampa, Florida, United States|Blade Research Site, Peoria, Illinois, United States|Blade Research Site, Metairie, Louisiana, United States|Blade Research Site, Baltimore, Maryland, United States|Blade Research Site, Detroit, Michigan, United States|Blade Research Site, Saint Louis, Missouri, United States|Blade Research Site, North Las Vegas, Nevada, United States|Blade Research Site, Durham, North Carolina, United States|Blade Research Site, Fayetteville, North Carolina, United States|Blade Research Site, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",NA,https://ClinicalTrials.gov/show/NCT04334460,Remdesivir
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,1,NCT04317092,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),TOCIVID-19,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab Injection,"One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples",All,"Child, Adult, Older Adult",Phase 2,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIVID-19|2020-001110-38,"March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",NA,"April 7, 2020","Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",NA,https://ClinicalTrials.gov/show/NCT04317092,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,2,NCT04345445,Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Drug: Methylprednisolone,The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay,University of Malaya,All,"18 Years and older   (Adult, Older Adult)",Phase 3,310,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TVCS-COVID19,"April 15, 2020","October 31, 2020","October 31, 2020","April 14, 2020",NA,"April 14, 2020","University Malaya Medical Centre, Kuala Lumpur, Malaysia",NA,https://ClinicalTrials.gov/show/NCT04345445,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,3,NCT04331795,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",COVIDOSE,Completed,No Results Available,COVID-19,Drug: Tocilizumab,Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline,University of Chicago,All,"18 Years and older   (Adult, Older Adult)",Phase 2,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB20-0515,"April 4, 2020","June 5, 2020","June 5, 2020","April 2, 2020",NA,"June 9, 2020","University of Chicago Medicine, Chicago, Illinois, United States",NA,https://ClinicalTrials.gov/show/NCT04331795,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,4,NCT04412772,A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS,ARCHITECTS,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Drug: Placebo,Clinical status (on a 7-point ordinal scale) at day 28|Clinical improvement|Mechanical Ventilation|Oxygenation,Queen's Medical Centre,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 3,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RA-2020-019,"June 1, 2020","December 31, 2021","December 31, 2021","June 2, 2020",NA,"June 2, 2020","Queen's Medical Center, Honolulu, Hawaii, United States",NA,https://ClinicalTrials.gov/show/NCT04412772,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,5,NCT04377750,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,NA,Recruiting,No Results Available,Covid19 Pneumonia,Drug: Tocilizumab,Survival,Hadassah Medical Organization|Sheba Medical Center|Wolfson Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0224-20-HMO-CTIL,"April 8, 2020","April 29, 2020","May 8, 2021","May 6, 2020",NA,"May 6, 2020","Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel|Barzilai Medical Center, Ashkelon, Israel|Wolfson Medical Center, H̱olon, Israel|Sheba Medical Center, Ramat Gan, Israel",NA,https://ClinicalTrials.gov/show/NCT04377750,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,6,NCT04361032,"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia",TRONCHER,Not yet recruiting,No Results Available,COVID19|Intensive Care Unit,Drug: Tocilizumab Injection|Drug: Deferoxamine,the mortality rate,Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,260,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ECC2020-06,"May 4, 2020","September 4, 2020","October 4, 2020","April 24, 2020",NA,"May 6, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia",NA,https://ClinicalTrials.gov/show/NCT04361032,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,7,NCT04359667,Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,UHID-COVID19,Not yet recruiting,No Results Available,COVID-19|Severe Pneumonia,Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA],serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab,"University Hospital for Infectious Diseases, Croatia",All,"18 Years and older   (Adult, Older Adult)",NA,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,UHID-04,"June 16, 2020","April 16, 2021","May 15, 2021","April 24, 2020",NA,"June 9, 2020","University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",NA,https://ClinicalTrials.gov/show/NCT04359667,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,8,NCT04332094,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",TOCOVID,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin,In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III,All,"18 Years and older   (Adult, Older Adult)",Phase 2,276,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIBSP-COV-2020-23,"April 2, 2020",September 2020,October 2020,"April 2, 2020",NA,"April 7, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",NA,https://ClinicalTrials.gov/show/NCT04332094,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,9,NCT04377659,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,NA,Recruiting,No Results Available,COVID-19,Drug: Tocilizumab,Progression of respiratory failure or death,Memorial Sloan Kettering Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-185,"May 1, 2020","May 1, 2021","May 1, 2021","May 6, 2020",NA,"May 29, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",NA,https://ClinicalTrials.gov/show/NCT04377659,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,10,NCT04424056,"An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease",INFLAMMACOV,Not yet recruiting,No Results Available,Covid19,Drug: Anakinra +/- Ruxolitinib (stages 2b/3)|Drug: Anakinra and Ruxolitinib (Advanced stage 3)|Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)|Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)|Other: Standard of care,Ventilation free days at D28,Assistance Publique Hopitaux De Marseille,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,216,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-23,"September 1, 2020","September 30, 2022","November 1, 2022","June 9, 2020",NA,"June 9, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",NA,https://ClinicalTrials.gov/show/NCT04424056,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,11,NCT04346355,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab,Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count,Azienda Unità Sanitaria Locale Reggio Emilia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,398,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RCT-TCZ-COVID-19|2020-001386-37,"March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",NA,"June 9, 2020","Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy",NA,https://ClinicalTrials.gov/show/NCT04346355,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,12,NCT04335071,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),CORON-ACT,Recruiting,No Results Available,SARS-CoV-2 Infection,Drug: Tocilizumab (TCZ)|Drug: Placebo,Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days),"University Hospital Inselspital, Berne|Roche Pharma AG",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2020-00691|2020DR2044,"April 26, 2020",October 2020,October 2020,"April 6, 2020",NA,"April 28, 2020","University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Lugano (EOC), Viganello, Switzerland|University Hospital Zurich, Zurich, Switzerland",NA,https://ClinicalTrials.gov/show/NCT04335071,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,13,NCT04412291,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",NA,Not yet recruiting,No Results Available,Covid-19,Drug: Anakinra Prefilled Syringe|Drug: Tocilizumab Prefilled Syringe|Drug: Standard-of-care treatment,"Time to recovery|Mortality|Number of Days on mechanical ventilation|Number of days of supplemental oxygen use|Number of patients requiring initiation of mechanical ventilation|Time to improvement in oxygenation for at least 48 hours|Mean change in the 8-point ordinal scale|Proportion of patients on level e-h on the 8-point ordinal scale at day 15|Time to improvement in one category from admission using the 8-point ordinal scale|Mean change in Sequential organ failure assessment score (SOFA)|Time to resolution of fever for at least 48 hours by clinical severity|Time to change in National Early Warning Score 2 (NEWS2) scoring system|Time to score of <2 maintained for 24 hours in NEWS2 scoring system (National Early Warning Score)|Mean change in NEWS2 scoring system (National Early Warning Score)|Number of days with fever|Number of days of resting respiratory rate >24 breaths/min|Time to saturation ≥94% on room air|Incidence of serious adverse events|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Number of ventilator free days in the first 28 days|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients requiring Extracorporeal membrane oxygenation (ECMO)|Number of patients that have been admitted into an intensive care unit (ICU)|Number of days of hospitalization in survivors|Number of deaths due to any cause",Jon Lampa|Karolinska University Hospital|Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-001748-24,June 2020,August 2020,February 2021,"June 2, 2020",NA,"June 4, 2020","Karolinska University Hospital, Huddinge, Stockholm, Sweden",NA,https://ClinicalTrials.gov/show/NCT04412291,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,14,NCT04403685,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,TOCIBRAS,Recruiting,No Results Available,COVID|SARS Pneumonia|Cytokine Release Syndrome,Drug: Tocilizumab,Evaluation of clinical status|All-cause mortality|Inpatient Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events,Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCIBRAS,"May 8, 2020","July 8, 2020","August 31, 2020","May 27, 2020",NA,"May 28, 2020","UNIFESP, São Paulo, Sao Paulo, Brazil|HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil|HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil|Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil|HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil|HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil|HSL - Hospital Sírio Libanês, Sao Paulo, Brazil",NA,https://ClinicalTrials.gov/show/NCT04403685,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,15,NCT04356937,Efficacy of Tocilizumab on Patients With COVID-19,NA,Not yet recruiting,No Results Available,SARS-CoV 2,Drug: Tocilizumab|Drug: Placebos,Proportion of patients that require mechanical ventilation|Requirement for inotropes and/or vasopressors|8-level Clinical improvement Scale|Duration of mechanical ventalition|Hospital discharge|Mortality|Duration of ICU stay|Duration of time on supplemental oxygen|The proportion of patients who require renal replacement therapy or have doubling of creatinine,"Massachusetts General Hospital|Genentech, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,300,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2020P001159,"April 27, 2020","June 30, 2020","August 30, 2020","April 22, 2020",NA,"April 22, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",NA,https://ClinicalTrials.gov/show/NCT04356937,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,16,NCT04372186,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Placebo|Drug: Tocilizumab,"Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,379,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ML42528,"May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",NA,"May 29, 2020","Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|Scripps Mercy Hospital, Chula Vista, California, United States|El Centro Regional Medical Center, El Centro, California, United States|eStudySite, La Mesa, California, United States|Riverside University Health System-Medical Center, Moreno Valley, California, United States|Highland Hospital Oakland, Oakland, California, United States|San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Howard University, Washington, District of Columbia, United States|Westchester General Hospital, Miami, Florida, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Uni of Kansas Medical Center, Kansas City, Kansas, United States|Ochsner Clinic, New Orleans, Louisiana, United States|LSU-Shreveport, Shreveport, Louisiana, United States|Holy Cross Germantown Hospital, Germantown, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Optum Health Care, Las Vegas, Nevada, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|St. Barnabas Hospital, Bronx, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Flushing Hospital, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Harlem Hospital, New York, New York, United States|Canton-Potsdam Hospital, Potsdam, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Sanford Health System, Sioux Falls, South Dakota, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States",NA,https://ClinicalTrials.gov/show/NCT04372186,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,17,NCT04320615,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,COVACTA,"Active, not recruiting",No Results Available,COVID-19 Pneumonia,Drug: Tocilizumab (TCZ)|Drug: Placebo,"Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42380|2020-001154-22,"April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",NA,"June 1, 2020","University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Intermountain Medical Group, Saint George, Utah, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|HOPITAL COCHIN university hospital, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany|Uniklinik Köln, Köln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|University College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St George's Clinical Research Facility, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT04320615,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,18,NCT04363736,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,MARIPOSA,Recruiting,No Results Available,COVID-19 Pneumonia,Drug: Tociliuzumab,Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA42481,"May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",NA,"June 2, 2020","Mayo Clinic - Arizona, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|LAC + USC Medical Center, Los Angeles, California, United States|USC Keck Medical Center of USC, Los Angeles, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|University of Florida; Health Science Center, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|MedPharmics, Metairie, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Renown Institute for Heart & Vascular Health, Reno, Nevada, United States|St Joseph's Regional Medical Center, Wayne, New Jersey, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States",NA,https://ClinicalTrials.gov/show/NCT04363736,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,19,NCT04377503,Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19,NA,Not yet recruiting,No Results Available,Cytokine Release Syndrome|Covid-19,Drug: Tocilizumab 180 MG/ML|Drug: Methylprednisolone Sodium Succinate,Patient clinical status 15 days after randomization|Improving oxygenation|Thorax CT improvement|ICU length of stay|Duration of mechanical ventilation|Incidence of acute kidney (AKI) with necessity of renal replacement therapy,Hospital Sao Domingos,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,covid-19 hsd,May 2020,August 2020,November 2020,"May 6, 2020",NA,"May 6, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04377503,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,20,NCT04332913,Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia,TOSCA,Recruiting,No Results Available,COVID-19 Pneumonia,NA,"Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases",University of L'Aquila,All,"18 Years and older   (Adult, Older Adult)",NA,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,0064468/20,"April 1, 2020","December 31, 2020","March 31, 2021","April 3, 2020",NA,"April 13, 2020","Ospedale San Salvatore, L'Aquila, Italy",NA,https://ClinicalTrials.gov/show/NCT04332913,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,21,NCT04363853,Tocilizumab Treatment in Patients With COVID-19,NA,Recruiting,No Results Available,Sars-CoV2,Drug: Tocilizumab,Hematic biometry|Blood chemistry|Blood gas|blood gas|thorax radiography,Instituto Nacional de Cancerologia de Mexico|Roche Pharma AG,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,200,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INF-3343-20-22-1,"April 1, 2020","June 1, 2020","August 1, 2020","April 27, 2020",NA,"April 27, 2020","National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico",NA,https://ClinicalTrials.gov/show/NCT04363853,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,22,NCT04409262,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,REMDACTA,Not yet recruiting,No Results Available,COVID-19 Pneumonia,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,"Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use",Hoffmann-La Roche|Gilead Sciences,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA42511|2020-002275-34,"May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",NA,"June 1, 2020","eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Michael'S Medical Center, Newark, New Jersey, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States",NA,https://ClinicalTrials.gov/show/NCT04409262,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,23,NCT04335305,Checkpoint Blockade in COVID-19 Pandemic,COPERNICO,Recruiting,No Results Available,"COVID-19|Pneumonia, Viral",Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),"Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)",MedSIR,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP376,"July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",NA,"June 9, 2020","Hospital Quirónsalud Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Arnau de Vilanova-Lliria, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain",NA,https://ClinicalTrials.gov/show/NCT04335305,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,24,NCT04306705,Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,TACOS,Recruiting,No Results Available,Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab,Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy,"Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells",Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",NA,120,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,WHTJCOVID-19,"February 20, 2020","May 30, 2020","June 20, 2020","March 13, 2020",NA,"March 17, 2020","Tongji Hospital, Wuhan, Hubei, China",NA,https://ClinicalTrials.gov/show/NCT04306705,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,25,NCT04310228,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NA,Recruiting,No Results Available,COVID-19,Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab,Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time,Peking University First Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020YFC0844100,"March 8, 2020",May 2020,May 2020,"March 17, 2020",NA,"April 10, 2020","Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China",NA,https://ClinicalTrials.gov/show/NCT04310228,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,26,NCT04370834,Tocilizumab for Patients With Cancer and COVID-19 Disease,NA,Recruiting,No Results Available,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Pneumonia|Pneumonitis|Severe Acute Respiratory Distress Syndrome|Symptomatic COVID-19 Infection Laboratory-Confirmed,Biological: Tocilizumab,Frequency of response|Length of time from level of care to step down level of care|Survival,National Cancer Institute (NCI),All,"2 Years and older   (Child, Adult, Older Adult)",Phase 2,200,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,NCI-2020-02987|TRC-10446,"May 28, 2020","January 1, 2022","January 1, 2022","May 1, 2020",NA,"June 9, 2020","National Cancer Institute, Rockville, Maryland, United States",NA,https://ClinicalTrials.gov/show/NCT04370834,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,27,NCT04339712,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,ESCAPE,Recruiting,No Results Available,COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection,Drug: Anakinra|Drug: Tocilizumab,Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function,Hellenic Institute for the Study of Sepsis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESCAPE|2020-001039-29,"April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",NA,"April 22, 2020","2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece|Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece",NA,https://ClinicalTrials.gov/show/NCT04339712,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,28,NCT04315480,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,NA,"Active, not recruiting",No Results Available,SARS Pneumonia,Drug: Tocilizumab,arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death,Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,38,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOCICOV-1,"March 12, 2020","April 9, 2020",May 2020,"March 19, 2020",NA,"April 13, 2020","Università Politecnica delle Marche, Ancona, AN, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04315480,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,29,NCT04333914,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,IMMUNONCOVID,Recruiting,No Results Available,SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor,Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA),Centre Leon Berard,All,"18 Years and older   (Adult, Older Adult)",Phase 2,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET20-076 - IMMUNONCOVID-20|2020-001373-70,"April 15, 2020",June 2020,August 2020,"April 3, 2020",NA,"June 9, 2020","Centre Léon Bérard, Lyon, Rhône, France|CHU Clermont Ferrand, Clermont Ferrand, France|Centre Oscar Lambret, Lille, France|AP-HP Hôpital Saint Antoine, Paris, France|AP-HP La Pitié Salpétrière, Paris, France|Hôpital Saint-Joseph, Paris, France|AP-HP Tenon, Paris, France|AP-HP Hôpital Bichat Claude Bernard, Paris, France|GH Diaconesses Croix Saint Simon, Paris, France|Gustave Roussy, Villejuif, France",NA,https://ClinicalTrials.gov/show/NCT04333914,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,30,NCT04423042,Tocilizumab in Coronavirus-19 Positive Patients,NA,Not yet recruiting,No Results Available,Covid19|COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2|Coronavirus|Inflammation,Biological: Tocilizumab,"All-cause mortality|Ordinal Scale for evaluating subject clinical status at days 3, 8, 15, 30, 60 post treatment.",University of Calgary|Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REB20-0713,June 2020,June 2021,June 2021,"June 9, 2020",NA,"June 9, 2020",NA,NA,https://ClinicalTrials.gov/show/NCT04423042,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,31,NCT04361552,Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),NA,Recruiting,No Results Available,Cerebrovascular Accident|Chronic Obstructive Pulmonary Disease|Chronic Renal Failure|Coronary Artery Disease|Diabetes Mellitus|Malignant Neoplasm|SARS Coronavirus 2 Infection,Other: Best Practice|Biological: Tocilizumab,7-day length of invasive mechanical ventilation (MV)|30-day mortality rate|Rate of intensive care (ICU) transfer|Rate of invasive mechanical ventilation|Rate of tracheostomy|Length of ICU stay|Length of hospital stay,Emory University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 3,180,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000419|NCI-2020-02314|WINSHIP4998-20|P30CA138292,"May 30, 2020","May 30, 2022","May 30, 2022","April 24, 2020",NA,"April 24, 2020","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",NA,https://ClinicalTrials.gov/show/NCT04361552,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,32,NCT04380519,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NA,Recruiting,No Results Available,COVID-19,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,"Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL04041078,"April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",NA,"May 8, 2020","Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation|АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation",NA,https://ClinicalTrials.gov/show/NCT04380519,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,33,NCT04330638,Treatment of COVID-19 Patients With Anti-interleukin Drugs,COV-AID,Recruiting,No Results Available,COVID-19,Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,"Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,342,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV-AID,April 2020,September 2020,December 2020,"April 1, 2020",NA,"April 24, 2020","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jessa ZH, Hasselt, Belgium|University Hospital Brussels, Jette, Belgium|CHU Tivoli, La Louvière, Belgium|CHR de la Citadelle, Liège, Belgium|University Hospital Liège, Liège, Belgium|Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium|AZ Delta, Roeselare, Belgium",NA,https://ClinicalTrials.gov/show/NCT04330638,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,34,NCT04322773,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,TOCIVID,Recruiting,No Results Available,Corona Virus Disease,Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care,Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events,Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APPI2-CV-2020-01,"April 5, 2020","June 1, 2021","June 1, 2021","March 26, 2020",NA,"April 7, 2020","Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark",NA,https://ClinicalTrials.gov/show/NCT04322773,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,35,NCT04386239,Study on the Use of Sarilumab in Patients With COVID-19 Infection,NA,Not yet recruiting,No Results Available,COVID19,Drug: Sarilumab Prefilled Syringe,Proportion of patients who show an improvement of the respiratory function|Evaluation of the time to resolution of fever|Evaluation of the viral load on blood and sputum for COVID-19|Evaluation of the plasma concentration of GM-CSF|Evaluation of the plasma concentration of Il-6|Evaluation of the plasma concentration of TNF-α|Evaluation of the rate of progression of White Blood Cell (WBC) fraction,ASST Fatebenefratelli Sacco,All,"18 Years to 84 Years   (Adult, Older Adult)",Early Phase 1,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COVID-SARI-001,May 2020,December 2020,December 2020,"May 13, 2020",NA,"May 13, 2020",NA,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04386239/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04386239,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,36,NCT04381936,Randomised Evaluation of COVID-19 Therapy,RECOVERY,Recruiting,No Results Available,Severe Acute Respiratory Syndrome,Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab,All-cause mortality|Duration of hospital stay|Need for (and duration of) ventilation|Composite endpoint of death or need for mechanical ventilation or ECMO,"University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Clinical Trials Unit Support Funding",All,"Child, Adult, Older Adult",Phase 2|Phase 3,12000,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NDPHRECOVERY|2020-001113-21|ISRCTN50189673,"March 19, 2020",December 2020,June 2021,"May 11, 2020",NA,"June 5, 2020","Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT04381936,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,37,NCT04331808,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),CORIMUNO-TOC,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Tocilizumab,Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-1,"March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",NA,"April 28, 2020","APHP- Hopital Tenon, Paris, France|APHP - Beaujon, Paris, France|APHP - Bichat, Paris, France|APHP - Hopital Necker, Paris, France|APHP - Pitié Salpêtrière, Paris, France|APHP - Saint Louis, Paris, France|CHU Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",NA,https://ClinicalTrials.gov/show/NCT04331808,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,38,NCT04366206,Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,NA,Recruiting,No Results Available,COVID|SARS-CoV 2,NA,Composite of death and mechanical ventilation|Need for mechanical ventilation|Death|Acute kidney injury|Acute respiratory distress syndrome|Cardiac arrhythmia and conduction disorder|60-days mortality|60-days mechanical ventilation,Centre Hospitalier Intercommunal Robert Ballanger|Groupe Hospitalier Pitie-Salpetriere,All,"Child, Adult, Older Adult",NA,143,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GHTRB-2020-01,"March 14, 2020","July 31, 2020","July 31, 2020","April 28, 2020",NA,"April 28, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Groupe Hospitalier Pitie Salpetriere, Paris, France",NA,https://ClinicalTrials.gov/show/NCT04366206,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,39,NCT04409522,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,NA,Recruiting,No Results Available,COVID-19,Drug: Melatonin|Drug: The usual treatment,Melatonin|Inflammatory cytokines|C-reactive protein (CRP)|Cough|Oxygen saturation of the blood|ESR|Radiological Treatment Response|Inflammatory route,Mohammad Sadegh Bagheri Baghdasht|Baqiyatallah Medical Sciences University,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IR.BMSU.REC.1399.039,"May 12, 2020","June 5, 2020","September 25, 2020","June 1, 2020",NA,"June 1, 2020","Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",NA,https://ClinicalTrials.gov/show/NCT04409522,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,40,NCT04359095,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NA,Not yet recruiting,No Results Available,COVID-19,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",NA,"April 24, 2020","Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia",NA,https://ClinicalTrials.gov/show/NCT04359095,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,41,NCT04347031,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,NA,"Active, not recruiting",No Results Available,"Pneumonia, Viral|Respiratory Failure",Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab,1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2,Burnasyan Federal Medical Biophysical Center,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FL-01/20,"April 8, 2020","August 1, 2020","August 1, 2020","April 15, 2020",NA,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",NA,https://ClinicalTrials.gov/show/NCT04347031,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,42,NCT04365764,Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NA,Recruiting,No Results Available,Covid-19|ARDS|Pneumonia,NA,Composite of death and mechanical ventilation|Death|Mechanical ventilation|World Health Organization score,Groupe Hospitalier Pitie-Salpetriere|Centre Hospitalier Intercommunal Robert Ballanger|Centre Hospitalier Intercommunal Montfermeil-Le Raincy|CMC Ambroise Paré,All,"Child, Adult, Older Adult",NA,400,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,CIC1421-20-06,"March 14, 2020","May 31, 2020","December 31, 2020","April 28, 2020",NA,"May 20, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France",NA,https://ClinicalTrials.gov/show/NCT04365764,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,43,NCT04388514,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,CORMOR,Recruiting,No Results Available,SARS-CoV-2 Respiratory Failure,Procedure: Medical Ozone procedure,Time of respiratory improvement and earlier weaning from oxygen support|The time of respiratory improvement and earlier weaning from oxygen support|Assessment of the length of hospitalization|Assessment of the length of Intensive Care Unit (ICU) stay|Improvment in chest imaging finding|Improvment in cytokine release syndrome,"Azienda Sanitaria-Universitaria Integrata di Udine|Fondazione Toscana Gabriele Monasterio|Policlinico Militare, Roma - Italy|Ospedale San Liberatore di Atri|Ospedale Umberto I di Torino|Università di Siena|Ospedale Civile di Lucca|Ospedale di Siracusa|Azienda Sanitaria Locale di Vercelli",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,CIG: Z7C2CA5837,"April 8, 2020","October 8, 2020","October 8, 2020","May 14, 2020",NA,"May 14, 2020","Dott. Amato De Monte, Udine, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04388514/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04388514,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,44,NCT04380818,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,NA,Recruiting,No Results Available,"Pneumonia, Viral",Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply,Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1,Grupo de Investigación Clínica en Oncología Radioterapia|Hospital Universitario Madrid Sanchinarro|Hospital del Mar|Hospital Universitari Sant Joan de Reus,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,106,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IPACOVID,"May 8, 2020","May 4, 2021","July 1, 2021","May 8, 2020",NA,"June 1, 2020","Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain",NA,https://ClinicalTrials.gov/show/NCT04380818,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,45,NCT02735707,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",REMAP-CAP,Recruiting,No Results Available,"Community-acquired Pneumonia, Influenza, COVID-19",Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab,All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome,MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584,"April 11, 2016",December 2021,December 2023,"April 13, 2016",NA,"April 16, 2020","St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02735707,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,46,NCT04349410,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,FMTVDM,Enrolling by invitation,No Results Available,CoVid 19 Positive,"Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum",Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status,The Camelot Foundation,All,"Child, Adult, Older Adult",Phase 2|Phase 3,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,FMTVDM2020,"April 11, 2020","October 11, 2020","November 11, 2020","April 16, 2020",NA,"April 17, 2020","FHHI-OI-Camelot; QME, Los Angeles, California, United States",NA,https://ClinicalTrials.gov/show/NCT04349410,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,47,NCT04374539,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,REP-COVID,Recruiting,No Results Available,Coronavirus,Biological: Plasma exchange|Drug: Standar medical treatmen,Impact of plasma exchange,Fundacion Clinic per a la Recerca Biomédica,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,116,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-001722-66,"April 29, 2020","May 5, 2021","August 29, 2021","May 5, 2020",NA,"May 5, 2020","Hospital Clinic i Provincial de Barcelona, Barcelona, Spain",NA,https://ClinicalTrials.gov/show/NCT04374539,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,48,NCT04346693,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,NA,"Active, not recruiting",No Results Available,Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia,Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation,The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study,Burnasyan Federal Medical Biophysical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAL-05-04-2020,"April 8, 2020",December 2020,December 2020,"April 15, 2020",NA,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",NA,https://ClinicalTrials.gov/show/NCT04346693,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,49,NCT04335123,Study of Open Label Losartan in COVID-19,NA,Recruiting,No Results Available,COVID-19,Drug: Losartan,"Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg",University of Kansas Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00145514,"March 25, 2020",September 2020,October 2020,"April 6, 2020",NA,"April 24, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",NA,https://ClinicalTrials.gov/show/NCT04335123,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,50,NCT04394182,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,ULTRA-COVID,Recruiting,No Results Available,"Pneumonia, Viral|Cytokine Storm",Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab,Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity,Fundacion GenesisCare|Hospital La Milagrosa|Hospital Vithas Valencia Consuelo,All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20.4.1597-GHM,"April 21, 2020","December 31, 2020","April 21, 2021","May 19, 2020",NA,"May 19, 2020","Hospital La Milagrosa, GenesisCare, Madrid, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain",NA,https://ClinicalTrials.gov/show/NCT04394182,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,51,NCT04366245,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NA,Recruiting,No Results Available,SARS-CoV 2,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,"Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.",Andalusian Network for Design and Translation of Advanced Therapies,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC/COVID-19,"April 23, 2020",December 2021,December 2021,"April 28, 2020",NA,"June 5, 2020","Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital U. Puerto Real, Puerto Real, Cádiz, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Hospital U. Torrecárdenas, Almería, Spain|Hospital U. Puerta del Mar, Cádiz, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. San Cecilio, Granada, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Hospital Regional U. de Málaga, Málaga, Spain|Hospital U. Virgen de la Victoria, Málaga, Spain|Hospital Unversitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital U. Nuestra Señora de Valme, Sevilla, Spain|Hospital San Juan de Dios, Sevilla, Spain",NA,https://ClinicalTrials.gov/show/NCT04366245,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,52,NCT04392414,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,NA,Recruiting,No Results Available,COVID-19,Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma),"The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|Dynamics of the level of C-reactive protein|30-day mortality rate","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CovPlas-Covid19,"May 1, 2020","August 1, 2020","September 15, 2020","May 18, 2020",NA,"June 4, 2020","Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",NA,https://ClinicalTrials.gov/show/NCT04392414,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,53,NCT04414631,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,NA,Not yet recruiting,No Results Available,Coronavirus Infections,Drug: Conestat alfa,Disease severity|Time to clinical improvement|Proportion of participants alive and not having required invasive or non-invasive ventilation|Proportion of subjects with an ALI (defined by PaO2/FiO2 ratio of <300mmHg),"University Hospital, Basel, Switzerland|Pharming Technologies B.V.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,120,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-01252; me20Osthoff3,June 2020,June 2021,July 2021,"June 4, 2020",NA,"June 4, 2020","University Hospital Basel, Division of Internal Medicine, Basel, Switzerland",NA,https://ClinicalTrials.gov/show/NCT04414631,Tocilizumab
data/clinical-trials-gov/2020-06-10/2020-06-10-clinical-trials-tocilizumab.csv,54,NCT04278404,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",POPS or POP02,Recruiting,No Results Available,"Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling,"Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"up to 20 Years   (Child, Adult)",NA,5000,Other|Industry|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,Pro00103838,"March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",NA,"May 14, 2020","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",NA,https://ClinicalTrials.gov/show/NCT04278404,Tocilizumab
